309 related articles for article (PubMed ID: 24404866)
41. Nano-assemblies of J-aggregates based on a NIR dye as a multifunctional drug carrier for combination cancer therapy.
Song X; Zhang R; Liang C; Chen Q; Gong H; Liu Z
Biomaterials; 2015 Jul; 57():84-92. PubMed ID: 25913253
[TBL] [Abstract][Full Text] [Related]
42. Simultaneous delivery of doxorubicin and curcumin encapsulated in liposomes of pegylated RGDK-lipopeptide to tumor vasculature.
Barui S; Saha S; Mondal G; Haseena S; Chaudhuri A
Biomaterials; 2014 Feb; 35(5):1643-56. PubMed ID: 24239109
[TBL] [Abstract][Full Text] [Related]
43. Disaccharide-modified liposomes and their in vitro intracellular uptake.
Song CK; Jung SH; Kim DD; Jeong KS; Shin BC; Seong H
Int J Pharm; 2009 Oct; 380(1-2):161-9. PubMed ID: 19635539
[TBL] [Abstract][Full Text] [Related]
44. Increased tumor targeted delivery using a multistage liposome system functionalized with RGD, TAT and cleavable PEG.
Mei L; Fu L; Shi K; Zhang Q; Liu Y; Tang J; Gao H; Zhang Z; He Q
Int J Pharm; 2014 Jul; 468(1-2):26-38. PubMed ID: 24709209
[TBL] [Abstract][Full Text] [Related]
45. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S
Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160
[TBL] [Abstract][Full Text] [Related]
46. Potent retro-inverso D-peptide for simultaneous targeting of angiogenic blood vasculature and tumor cells.
Li Y; Lei Y; Wagner E; Xie C; Lu W; Zhu J; Shen J; Wang J; Liu M
Bioconjug Chem; 2013 Jan; 24(1):133-43. PubMed ID: 23241015
[TBL] [Abstract][Full Text] [Related]
47. The effect of liposomal size on the targeted delivery of doxorubicin to Integrin αvβ3-expressing tumor endothelial cells.
Kibria G; Hatakeyama H; Ohga N; Hida K; Harashima H
Biomaterials; 2013 Jul; 34(22):5617-27. PubMed ID: 23623323
[TBL] [Abstract][Full Text] [Related]
48. Targeted delivery of cargoes into a murine solid tumor by a cell-penetrating peptide and cleavable poly(ethylene glycol) comodified liposomal delivery system via systemic administration.
Kuai R; Yuan W; Li W; Qin Y; Tang J; Yuan M; Fu L; Ran R; Zhang Z; He Q
Mol Pharm; 2011 Dec; 8(6):2151-61. PubMed ID: 21981683
[TBL] [Abstract][Full Text] [Related]
49. Bio-distribution and anti-tumor efficacy of PEG/PLA nano particles loaded doxorubicin.
Yu JJ; Lee HA; Kim JH; Kong WH; Kim Y; Cui ZY; Park KG; Kim WS; Lee HG; Seo SW
J Drug Target; 2007 May; 15(4):279-84. PubMed ID: 17487696
[TBL] [Abstract][Full Text] [Related]
50. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region.
Amin M; Mansourian M; Koning GA; Badiee A; Jaafari MR; Ten Hagen TLM
J Control Release; 2015 Dec; 220(Pt A):308-315. PubMed ID: 26526970
[TBL] [Abstract][Full Text] [Related]
51. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models.
Gabizon A; Tzemach D; Mak L; Bronstein M; Horowitz AT
J Drug Target; 2002 Nov; 10(7):539-48. PubMed ID: 12683721
[TBL] [Abstract][Full Text] [Related]
52. Design of Y-shaped targeting material for liposome-based multifunctional glioblastoma-targeted drug delivery.
Belhadj Z; Ying M; Cao X; Hu X; Zhan C; Wei X; Gao J; Wang X; Yan Z; Lu W
J Control Release; 2017 Jun; 255():132-141. PubMed ID: 28390902
[TBL] [Abstract][Full Text] [Related]
53. Tumor-type-dependent vascular permeability constitutes a potential impediment to the therapeutic efficacy of liposomal oxaliplatin.
Abu Lila AS; Matsumoto H; Doi Y; Nakamura H; Ishida T; Kiwada H
Eur J Pharm Biopharm; 2012 Aug; 81(3):524-31. PubMed ID: 22554766
[TBL] [Abstract][Full Text] [Related]
54. [PEG-liposome in DDS and clinical studies].
Maruyama K
Nihon Rinsho; 1998 Mar; 56(3):632-7. PubMed ID: 9549348
[TBL] [Abstract][Full Text] [Related]
55. Ultrasound enhanced antitumor activity of liposomal doxorubicin in mice.
Hagtvet E; Evjen TJ; Olsen DR; Fossheim SL; Nilssen EA
J Drug Target; 2011 Sep; 19(8):701-8. PubMed ID: 21524240
[TBL] [Abstract][Full Text] [Related]
56. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol).
Parr MJ; Masin D; Cullis PR; Bally MB
J Pharmacol Exp Ther; 1997 Mar; 280(3):1319-27. PubMed ID: 9067319
[TBL] [Abstract][Full Text] [Related]
57. Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors.
Kibria G; Hatakeyama H; Sato Y; Harashima H
Int J Pharm; 2016 Jul; 509(1-2):178-187. PubMed ID: 27234700
[TBL] [Abstract][Full Text] [Related]
58. Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity.
Patil Y; Amitay Y; Ohana P; Shmeeda H; Gabizon A
J Control Release; 2016 Mar; 225():87-95. PubMed ID: 26809007
[TBL] [Abstract][Full Text] [Related]
59. Peptide dendrimer-Doxorubicin conjugate-based nanoparticles as an enzyme-responsive drug delivery system for cancer therapy.
Zhang C; Pan D; Luo K; She W; Guo C; Yang Y; Gu Z
Adv Healthc Mater; 2014 Aug; 3(8):1299-308. PubMed ID: 24706635
[TBL] [Abstract][Full Text] [Related]
60. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
